Lyle Feinstein, MD
Hematology & Oncology · Miami, FLNPI 1871589416
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,836 of the $116,044 with a category attached, or 84.3%. 14 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 39.7% of the total. Reporting peaked in 2019 at $64,630 and has fallen 99.1% since, to $567 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $834.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$46K
- Bristol Myers Squibb$21K
- Amgen$18K
- E.r. Squibb & Sons, L.L.C.$15K
- Novartis$14K
- Astellas Pharma US Inc$393
- plus $975 from 8 others
What the payments were for
- Consulting fees$4,5034%
- Speaking & faculty fees$97,83684%
- Travel & lodging$9,6698%
- Food & beverage$3,5443%
- Education$4920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $46,040 |
| Bristol Myers Squibb | 22 | $21,029 |
| Amgen | 23 | $18,155 |
| E.r. Squibb & Sons, L.L.C. | 10 | $15,213 |
| Novartis | 12 | $14,241 |
| Astellas Pharma US Inc | 4 | $393 |
| Johnson & Johnson | 6 | $372 |
| Sanofi | 3 | $267 |
| Pfizer | 5 | $106 |
| Adaptive Biotechnologies Corporation | 3 | $83 |
| Partner Therapeutics, Inc. | 3 | $55 |
| AstraZeneca | 2 | $48 |
| Gilead | 1 | $26 |
| Genentech USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,044 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.